Clinical Trial of Safety and Immunogenicity of Recombinant SARS-CoV-2 S-Trimer Vaccine (CHO Cells) as Booster Vaccination in Populations Aged 18 to 59 Years

NCT05716347 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

TERMINATED

Status

80

Enrollment

INDUSTRY

Sponsor class

Stopped Company strategy adjustment

Conditions

COVID-19

Interventions

BIOLOGICAL: the recombinant SARS-CoV-2 S-Trimer vaccine/inactivated SARS-CoV-2 vaccine

Sponsor

Binhui Biopharmaceutical Co., Ltd.